18F-Mefway Ligand for Stable PET Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current serotonin 5-HT1A receptor ligands face challenges such as rapid metabolism, short plasma elimination, chemical instability, and low affinity for the target receptor, making them unsuitable for effective PET and SPECT analysis.
Innovation Solution
Development of radiolabeled serotonin 5-HT1A receptor ligands, particularly 18F-Mefway, with a substituted arylpiperazinyl structure and an alkyl linker covalently bound to a tertiary amine and an aromatic ring, which is chemically stable and has high affinity for the receptor, suitable for PET and SPECT detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If known serotonin 5-HT1A receptor ligands are used for PET/SPECT analysis, then receptor binding is achieved, but rapid metabolism and short plasma elimination occur
Solution Approach 1:
The patent modifies molecular parameters of the ligand structure, specifically incorporating fluorinated aromatic rings and optimized linker groups, to alter metabolic stability and plasma half-life characteristics, thereby extending the duration of action for reliable data analysis
Solution Approach 2:
The invention creates composite molecular structures combining radiolabeled aromatic moieties with piperazinyl core structures and tailored linker groups, forming a composite ligand that achieves both receptor affinity and extended plasma stability
2Measurement precision
If 18F is used as a radiolabel for serotonin 5-HT1A receptor ligands, then PET detection capability is achieved, but chemical instability increases
Solution Approach 1:
The patent introduces stable linker groups and protective aromatic structures as intermediary elements between the 18F radiolabel and the receptor binding core, shielding the radiolabeled position from metabolic degradation while maintaining PET detectability
Solution Approach 2:
The invention extracts the radiolabel from positions prone to metabolic cleavage and relocates it to sterically protected aromatic positions, separating the detection function from vulnerable structural elements
3Measurement precision
If 18F-labeled compounds are synthesized for PET analysis, then radiodetection is achieved, but affinity to the target receptor decreases
Solution Approach 1:
The patent applies radiolabeling at specific local positions on the molecule (aromatic rings distant from the binding core) that do not interfere with the critical interaction zones, maintaining high receptor affinity while enabling PET detection
Solution Approach 2:
The invention segments the ligand into distinct functional modules: a receptor-binding core structure and a radiolabeled detection module connected by flexible linkers, allowing independent optimization of affinity and detectability
4Productivity
If synthesis of serotonin 5-HT1A receptor ligands is performed, then compound production is achieved, but synthesis yield is insufficient
Solution Approach 1:
The patent employs preliminary protection group strategies and pre-formed stable intermediates in the synthesis pathway, allowing modular assembly of the complex ligand structure with improved overall yield and reduced synthetic difficulty
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new ligands exhibit improved stability and specificity, allowing for effective PET analysis and measurement of serotonin levels in the brain, with high binding affinity and retention in receptor-rich regions, surpassing the performance of existing compounds.
Implementation Method 1
radiolabeled with a label that is detectable by PET and/or SPECT
Data Source
AI summary
Contemplated substituted arylpiperazinyl compounds, and most preferably 18F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with 18F-fluorine in a single step. Still further, contemplated compounds exhibit high target to non-target ratios in receptor-rich regions both in vitro and in vivo, and selected compounds can be effectively and sensitively displaced by serotonin, thus providing a quantitative tool for measuring 5-HT1A receptors and serotonin concentration changes in the living brain.